Drugs for Gastrointestinal Diseases Practice Questions

Q: Constipation is caused by all of the following drugs except?

Neostigmine. **Explanation:** The correct answer is **Neostigmine**. To understand this, one must look at the effect of the Autonomic Nervous System (ANS) on the gastrointestinal tract. **1. Why Neostigmine is the correct answer:** Neostigmine is an **Anticholinesterase** (parasympathomimetic). It inhibits the enzyme acetylcholinesterase, leading to increased levels of Acetylcholine (ACh) at the muscarinic receptors in the gut [1]. ACh stimulates the M3 receptors on intestinal smooth muscles, increasing peristalsis and secretions. Therefore, Neostigmine **promotes bowel evacuation** (prokinetic effect) and is actually used clinically to treat paralytic ileus and Ogilvie’s syndrome. It causes diarrhea, not constipation. **2. Why the other options are incorrect:** * **Atropine:** This is a classic **Antimuscarinic** (parasympatholytic). By blocking M3 receptors, it decreases intestinal motility and secretions, leading to constipation [2]. * **Morphine & Fentanyl:** These are **Opioids**. Opioids cause significant constipation (Opioid-Induced Constipation) by acting on $\mu$-receptors in the myenteric plexus [3]. This results in decreased rhythmic contractions, increased segmental tone (which slows transit), and increased water absorption from the stool. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Constipation Mnemonics:** Remember **"ABC"** — **A**nticholinergics (Atropine), **B**arium sulfate, **C**alcium channel blockers (Verapamil is a notorious cause), and **O**pioids. * **Verapamil** is the CCB most commonly associated with constipation in exam questions. * **Methylnaltrexone** or **Alvimopan** are specific $\mu$-opioid antagonists used to treat opioid-induced constipation without reversing analgesia.

Q: Which antibody has shown to be useful for Crohn's Disease?

Natalizumab. **Explanation:** **Natalizumab** is the correct answer because it is a humanized monoclonal antibody directed against **$\alpha$4-integrin**. In Crohn’s Disease (CD), inflammation is driven by the migration of leukocytes into the vascularized gastrointestinal mucosa. Natalizumab inhibits this process by blocking the interaction between $\alpha$4-integrins on leukocytes and **VCAM-1** (Vascular Cell Adhesion Molecule-1) on endothelial cells. It is typically reserved for patients with moderate-to-severe CD who have failed anti-TNF therapy. **Analysis of Incorrect Options:** * **Omalizumab (Option A):** This is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human **Immunoglobulin E (IgE)**. It is used in the management of severe persistent allergic asthma and chronic urticaria, not IBD. * **Palivizumab (Option B):** This is a monoclonal antibody directed against the F (fusion) protein of the **Respiratory Syncytial Virus (RSV)**. It is used for the prevention of serious lower respiratory tract disease caused by RSV in high-risk pediatric patients. **High-Yield Clinical Pearls for NEET-PG:** * **PML Risk:** The most significant adverse effect of Natalizumab is **Progressive Multifocal Leukoencephalopathy (PML)**, caused by the reactivation of the **JC virus**. * **Vedolizumab:** A more gut-selective alternative to Natalizumab. It targets the **$\alpha$4$\beta$7 integrin**, specifically blocking leukocyte migration to the gut without affecting the CNS, thereby carrying a much lower risk of PML. * **Other Biologics in CD:** Anti-TNF agents (Infliximab, Adalimumab), IL-12/23 inhibitors (Ustekinumab), and JAK inhibitors (Upadacitinib).

Q: Bisacodyl is classified as which of the following types of laxatives?

Stimulant purgative. **Explanation:** **Bisacodyl** is a diphenylmethane derivative that acts as a **stimulant purgative** (irritant laxative). It works by directly irritating the sensory nerve endings in the colonic mucosa, which stimulates myenteric plexus activity and increases propulsive peristalsis. Additionally, it inhibits the Na⁺/K⁺-ATPase enzyme, leading to the accumulation of water and electrolytes in the intestinal lumen, thereby facilitating evacuation. **Analysis of Options:** * **Bulk-forming laxatives (Option A):** These include natural or synthetic polysaccharides like **Psyllium (Isabgol)** and **Methylcellulose**. They absorb water, expand in the gut, and increase fecal mass to mechanically stimulate peristalsis. * **Stool softeners (Option B):** Also known as emollient laxatives, these include **Docusate** and **Liquid Paraffin**. They act as anionic surfactants that allow water and lipids to penetrate the stool, softening it. * **Osmotic purgatives (Option D):** These include **Magnesium salts, Lactulose, and Polyethylene Glycol (PEG)**. They are non-absorbable solutes that draw water into the intestinal lumen via osmosis, increasing intraluminal pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Bisacodyl primarily acts on the **colon**. * **Administration:** It is available as oral tablets (enteric-coated to prevent gastric irritation) and suppositories. The suppository form is rapid-acting (15–60 minutes), making it useful for bowel preparation before surgery or endoscopy. * **Side Effects:** Chronic use can lead to "Cathartic Colon" (loss of colonic tone) and hypokalemia. * **Contraindication:** It should not be used in patients with undiagnosed abdominal pain or intestinal obstruction.

Q: A patient with chronic renal failure has been diagnosed with a peptic ulcer. Which of the following anti-peptic ulcer medications should be administered to this patient?

Sucralfate.. **Explanation:** The correct answer is **Sucralfate**. **1. Why Sucralfate is the correct choice:** Sucralfate is a complex of sulfated sucrose and **aluminum hydroxide**. It acts locally by polymerizing in an acidic environment (pH < 4) to form a sticky, viscous gel that binds to the ulcer base, creating a physical barrier against acid and pepsin. Although it contains aluminum, it is **non-absorbable**. In patients with chronic renal failure (CRF), medications that are not absorbed systemically are preferred to avoid toxicity, making sucralfate a safe and effective mucosal protective agent. **2. Why the other options are incorrect:** * **Aluminum hydroxide (Option B):** While used as an antacid, chronic use in CRF patients leads to systemic absorption of aluminum. Since the kidneys cannot excrete it, it accumulates, leading to **aluminum toxicity**, which manifests as encephalopathy, osteomalacia, and proximal myopathy. * **Magnesium hydroxide (Option C):** Magnesium is primarily excreted by the kidneys. In CRF, magnesium clearance is impaired, leading to **hypermagnesemia**, which can cause muscle weakness, hypotension, and cardiac arrhythmias. * **All of the above (Option D):** This is incorrect because both pure aluminum and magnesium salts pose significant systemic risks in renal failure. **High-Yield NEET-PG Pearls:** * **Sucralfate Requirement:** It requires an acidic medium for activation; therefore, it should **not** be given simultaneously with antacids, H2 blockers, or PPIs (administer 30 minutes apart). * **Phosphate Binding:** Both Sucralfate and Aluminum hydroxide can bind dietary phosphate. While Aluminum hydroxide is used clinically as a phosphate binder in CRF, Sucralfate is the preferred choice for *ulcer management* due to its superior local protective action and minimal systemic absorption. * **Side Effect:** The most common side effect of Sucralfate is **constipation** (due to the aluminum component).

Q: Which of the following drugs possesses both 5-HT4 agonist and D2 antagonist properties?

Metoclopramide. **Metoclopramide** is a substituted benzamide used as a prokinetic and antiemetic [2]. Its mechanism of action is dual-faceted:1. **D2 Antagonism:** It blocks dopamine D2 receptors in the Chemoreceptor Trigger Zone (CTZ), providing its potent antiemetic effect. It also blocks inhibitory D2 receptors in the GI tract [1].2. **5-HT4 Agonism:** It acts as an agonist at 5-HT4 receptors on enteric cholinergic neurons. This stimulates the release of Acetylcholine (ACh), which increases gastric motility and lower esophageal sphincter (LES) tone, making it an effective prokinetic [1, 3].*Note: At high doses, it also possesses 5-HT3 antagonist properties [1].***Analysis of Incorrect Options:*** **A. Ondansetron:** It is a selective **5-HT3 antagonist** used primarily for chemotherapy-induced nausea and vomiting (CINV). It has no prokinetic activity or D2 blocking properties.* **C. Benzhexol (Trihexyphenidyl):** This is a **centrally acting anticholinergic** drug used in the management of Parkinson’s disease and drug-induced extrapyramidal symptoms.* **D. Ibutilide:** This is a **Class III antiarrhythmic** drug used for the acute conversion of atrial fibrillation or flutter to sinus rhythm.***High-Yield Pearls for NEET-PG:*** **Prokinetic Spectrum:** Metoclopramide increases LES tone and gastric emptying but has **no effect** on large bowel motility.* **Side Effects:** Due to D2 blockade in the CNS, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and **Hyperprolactinemia** (leading to galactorrhea/gynecomastia).* **Domperidone** is a similar D2 antagonist but does not cross the blood-brain barrier easily, resulting in fewer EPS compared to Metoclopramide.

Q: Which of the following statements about Octreotide is incorrect?

It acts as an absorbent.. ### Explanation **Correct Answer: D. It acts as an absorbent.** **1. Why Option D is the correct (incorrect statement):** Octreotide is a **pharmacological agent**, specifically a synthetic octapeptide analogue of the hormone somatostatin. It does not act physically as an absorbent (like Kaolin or Pectin, which bind toxins and water in the gut lumen). Instead, it works by binding to specific somatostatin receptors (SSTR-2, 3, and 5) to inhibit the secretion of various hormones and intestinal fluids. **2. Analysis of Incorrect Options (Correct Statements):** * **Option A:** Octreotide is indeed a **somatostatin analogue**. It is preferred over natural somatostatin because it has a much longer half-life (approx. 1.5 hours vs. 2 minutes) and can be administered subcutaneously or intravenously. * **Option B:** It is a standard treatment for **refractory secretory diarrhea** associated with AIDS and chemotherapy. It works by inhibiting intestinal secretion and enhancing water/electrolyte absorption. * **Option C:** It is the drug of choice for symptomatic relief in **Carcinoid Syndrome** and VIPomas. It suppresses the release of serotonin and other vasoactive peptides that cause flushing and diarrhea. **3. Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Inhibits the release of Growth Hormone (GH), Glucagon, Insulin, Gastrin, and VIP. * **Other Uses:** * **Acromegaly:** To reduce GH levels. * **Esophageal Varices:** It causes splanchnic vasoconstriction, reducing portal pressure (though Terlipressin is often preferred). * **Dumping Syndrome:** Post-gastrectomy. * **Key Side Effect:** **Gallstones (Cholelithiasis)** due to inhibition of cholecystokinin (CCK) release and reduced gallbladder contractility. * **Steatorrhea:** May occur due to inhibition of pancreatic enzyme secretion.

Q: All of the following are true for metoclopramide except?

Stimulates the chemoreceptor trigger zone. **Explanation:**Metoclopramide is a substituted benzamide, a prokinetic agent, and a potent antiemetic [1]. The correct answer is **Option C** because metoclopramide **blocks** (antagonizes) the Chemoreceptor Trigger Zone (CTZ), rather than stimulating it. **Why Option C is the correct answer (The Exception):**Metoclopramide acts as an antiemetic primarily by blocking **D2 receptors** in the CTZ of the medulla. By inhibiting these receptors, it raises the threshold for vomiting. Stimulating the CTZ would induce nausea and vomiting, which is the opposite of metoclopramide’s clinical use. **Analysis of Incorrect Options:** * **Option A (Chemically related to procainamide):** This is true. Metoclopramide is a derivative of para-aminobenzoic acid (PABA), making it chemically related to the antiarrhythmic drug procainamide, though it lacks significant antiarrhythmic activity. * **Option B (Speeds gastric emptying):** This is true. As a **prokinetic**, it increases lower esophageal sphincter tone and enhances gastric motility/emptying by blocking inhibitory D2 receptors and enhancing Acetylcholine release (5-HT4 agonism) in the enteric nervous system [2]. * **Option D (Blocks D2 receptors):** This is true. Its primary mechanism of action both centrally (antiemetic) and peripherally (prokinetic) involves D2 receptor antagonism. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Due to central D2 blockade, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and Parkinsonism. It also increases prolactin levels, leading to galactorrhea or gynecomastia. * **Drug of Choice:** It is frequently used for Diabetic Gastroparesis and as an antiemetic in post-operative states or chemotherapy [1]. * **Contraindication:** It must be avoided in patients with **Pheochromocytoma** (can cause hypertensive crisis) and mechanical GI obstruction.

Q: Which of the following drugs is NOT used in the management of IBS-Constipation?

Alosetron. **Explanation:** The correct answer is **Alosetron** because it is used in the management of **IBS-Diarrhea (IBS-D)**, not IBS-Constipation (IBS-C). **Mechanism and Rationale:** * **Alosetron** is a potent **5-HT₃ receptor antagonist**. By blocking these receptors in the enteric nervous system, it reduces intestinal motility, decreases secretions, and increases visceral pain thresholds. Because it slows colonic transit, it is indicated specifically for severe, diarrhea-predominant IBS in women who have not responded to conventional therapy. **Analysis of Incorrect Options (Drugs used for IBS-C):** * **Lubiprostone (Option A):** A **Chloride Channel Activator (Type-2)**. It increases fluid secretion into the intestinal lumen, which softens stool and accelerates transit time. * **Tegaserod (Option B):** A **5-HT₄ receptor partial agonist**. Stimulation of 5-HT₄ receptors triggers the peristaltic reflex and promotes gastric emptying and intestinal transit. (Note: Its use is restricted due to cardiovascular risks). * **Linaclotide (Option D):** A **Guanylate Cyclase-C (GC-C) agonist**. It increases intracellular cGMP, which activates the CFTR channel to secrete chloride and bicarbonate into the lumen, facilitating bowel movements and reducing visceral pain. **High-Yield NEET-PG Pearls:** 1. **Alosetron Warning:** It is associated with a rare but serious risk of **Ischemic Colitis**, requiring a strict prescribing program. 2. **Prucalopride:** Another 5-HT₄ agonist (highly selective) used for chronic constipation. 3. **Eluxadoline:** A mu-opioid receptor agonist used for IBS-D. 4. **Rifaximin:** A non-absorbable antibiotic often used for IBS-D to modulate gut flora.

Question 1

Constipation is caused by all of the following drugs except?

Accepted Answer

Neostigmine

Answer

Atropine

Answer

Morphine

Answer

Fentanyl

Question 2

Which antibody has shown to be useful for Crohn's Disease?

Accepted Answer

Natalizumab

Answer

Omalizumab

Answer

Palivizumab

Answer

None of the above

Question 3

A 46-year-old male presents with diarrhea and abdominal pain. Investigations reveal it to be non-infective. The patient is prescribed diphenoxylate therapy. What is the primary target of diphenoxylate in this patient?

Accepted Answer

Motility

Answer

Secretion

Answer

Digestion

Answer

Inflammation

Question 4

Bisacodyl is classified as which of the following types of laxatives?

Accepted Answer

Stimulant purgative

Answer

Bulk forming

Answer

Stool softener

Answer

Osmotic purgative

Question 5

A patient with chronic renal failure has been diagnosed with a peptic ulcer. Which of the following anti-peptic ulcer medications should be administered to this patient?

Accepted Answer

Sucralfate.

Answer

Aluminum hydroxide.

Answer

Magnesium hydroxide.

Answer

All of the above.

Question 6

Which of the following drugs possesses both 5-HT4 agonist and D2 antagonist properties?

Accepted Answer

Metoclopramide

Answer

Ondansetron

Answer

Benzhexol

Answer

Ibutilide

Question 7

Which of the following statements about Octreotide is incorrect?

Accepted Answer

It acts as an absorbent.

Answer

It is a somatostatin analogue.

Answer

It is used in secretory diarrhea in AIDS.

Answer

It is used in carcinoid syndrome.

Question 8

All of the following are true for metoclopramide except?

Accepted Answer

Stimulates the chemoreceptor trigger zone

Answer

Chemically related to procainamide

Answer

Speeds gastric emptying

Answer

Blocks D2 receptors

Question 9

Which of the following drugs is NOT used in the management of IBS-Constipation?

Accepted Answer

Alosetron

Answer

Lubiprostone

Answer

Tegaserod

Answer

Linaclotide

Question 10

All of the following are true regarding a patient with acid peptic disease except?

Accepted Answer

Omeprazole may help ulcers refractory to H2 blockers.

Answer

Misoprostol is the drug of choice in patients on NSAIDs.

Answer

Duodenal ulcer is preventable by the use of single nighttime H2 blockers.

Answer

Misoprostol is the drug of choice in pregnant patients.

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?